IMM2520

IMM2520 is a bispecific antibody-receptor fusion protein developed using the "mab-trap" platform that targets both CD47 and PD-L1, two immune checkpoint molecules commonly expressed on tumor cells. By binding to CD47, IMM2520 blocks the "do not eat me" signal that protects cancer cells from phagocytosis by macrophages (innate immunity), while its binding to PD-L1 inhibits the PD-1/PD-L1 pathway involved in suppressing T-cell activity (adaptive immunity). This dual blockade enhances anti-tumor immune responses through mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Preclinical studies show preferential binding to tumor cells co-expressing CD47 and PD-L1, with reduced off-target effects such as erythrocyte agglutination. IMM2520 is being developed primarily for advanced solid tumors and has entered phase 1 clinical trials. It is being developed by ImmuneOnco Biopharmaceuticals.